Sino Biopharm's New Indication Application for Combo Therapy Accepted in China
Sino Biopharmaceutical (01177.HK): The application for listing approval for the new indication of the combination of Bemarolizumab Injection and Anlotinib Hydrochloride Capsules for first-line treatment of advanced renal cell carcinoma has been accepted.
On August 1st, Gelon Hui announced that Sino Biopharmaceutical, which independently developed Innovative Drug Category 1 Pembrolizumab Injection combined with Innovative Drug Category 1 Anlotinib Hydrochloride Capsules, has submitted a new indication listing application to the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) and has been accepted, which is used for first-line treatment of advanced unresectable or metastatic renal cell carcinoma (RCC). Pembrolizumab Injection is a novel sequence innovative fully humanized Anti-PD-L1 monoclonal antibody developed by the Group, which was approved for listing by the NMPA in May 2024 and is used for
Express News | Sino Biopharmaceutical - Acceptance of New Indication Application for Marketing of Benmelstobart Injection by Nmpa
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Sino Biopharm (01177.HK) plans to hold a board of directors meeting on August 13 to approve its interim performance.
Sino Biopharm (01177.HK) announced that it will hold a board of directors meeting on Tuesday, August 13, 2024 to approve (including) the publication of unaudited interim results for the six-month period ending June 30, 2024 for the company and its subsidiaries, as well as to consider the distribution of interim dividends (if any).
SINO BIOPHARM: NOTIFICATION OF BOARD MEETING
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Citigroup: rates Sino Biopharm as "buy" with a target price of HKD 6.8.
According to a research report released by Citigroup, due to the strong sales growth of biosimilars and innovative drugs, it is expected that Sino Biopharmaceutical (01177) will perform well in the first half of the year, with a year-on-year profit growth of approximately 10%. Due to the increased sales of biosimilars, G-CSF, and Cataplasms, the company is expected to have higher visibility in the second half of the year. The bank has initiated a 30-day upside catalyst observation on the company, with a target price of HKD 6.8 and a rating of "buy".
Citi: Rated buy for Sino Biopharmaceutical (01177) with a target price of HKD 6.8.
Citigroup has initiated a 30-day upward catalyst observation on Sino Biopharmaceuticals (01177) in China.
Sino Biopharmaceutical Gets Selected by S&P Global, FTSE4Good Index for ESG Practices
Sino Biopharm (01177.HK): ESG performance recognized by S&P Global and FTSE Russell.
Sino Biopharm (01177.HK) announced on July 19th that the group has been recognized by multiple global sustainable development authorities, such as S&P Global and FTSE Russell, based on its continuous and stable environmental, social and corporate governance (ESG) performance.
Sino Biopharmaceutical's Phase-3 Trial of Breast Cancer Drug Reaches Primary Endpoint
Sino Biopharm (01177) under the Hong Kong stock connect program: Phase III clinical trials related to breast cancer treatment achieve the predetermined primary endpoint.
Sinobiopharm (01177) announced that the phase III clinical trial (NCT05375461) of type 1 innovative drug Culmerciclib (TQB3616) developed by the group and combined with fluvisinque injection for the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer that has been treated with endocrine therapy in the past has completed mid-term analysis and has achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major academic conferences.
Sino Biopharm (01177.HK): The new drug application for Class 1 innovative drug Culmerciclib (TQB3616) has been accepted for listing.
Sino Biopharm (01177.HK) announced that the Phase III clinical trial (NCT05375461) of the class 1 innovative drug Culmerciclib (TQB3616) developed by the group, combined with Fluvisumab injection for the treatment of Hormone Receptor (HR)-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy, has completed mid-term analysis and achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major publications.
Express News | Sino Biopharmaceutical - Acceptance by National Medical Products Administration
Express News | Sino Biopharmaceutical - Acceptance of New Drug Application for Category 1 Innvoative Drug Culmerciclib Capsule Culmerciclib (Tqb3616)
Sino Biopharmaceutical Soft Tissue Sarcoma Drug Gives Positive Phase III Trial Results
Sino Biopharmaceutical (01177.HK): Positive results obtained in phase III study of anlotinib hydrochloride capsules combined with chemotherapy for first-line treatment of advanced soft tissue sarcoma.
Sino Biopharm (01177.HK) announced on July 16th that the phase III clinical trial (ALTN-III-04) of Anlotinib Hydrochloride Capsules, a Type 1 innovative drug independently developed by the group, combined with chemotherapy for first-line treatment of advanced unresectable or metastatic soft tissue sarcoma, has completed the planned interim analysis. The independent data monitoring committee (IDMC) determined that the main research endpoint (PFS) did not progress and reached the planned superior efficacy boundary value, and the secondary endpoint (OS) showed a trend of benefit. The group has communicated with the drug evaluation center of the China National Medical Products Administration.
Express News | Sino Biopharmaceutical - Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule
No Data